Emcure Pharma shares slide 6% post-Q4 results on profit booking

Shares of Emcure Pharmaceuticals declined 6 percent in Tuesday’s trade after the company reported its March quarter earnings, with profit booking weighing on the stock.

The stock settled 6 percent lower at Rs 1,689 per share on the National Stock Exchange (NSE).

The company’s standalone price-to-earnings (PE) ratio stood at 49.90, compared with the Nifty Pharma PE of 35.

Emcure Pharmaceuticals reported a 24 percent increase in consolidated net profit at Rs 243.74 crore for the fourth quarter ended March 2026, driven by growth in its international business. It had posted a consolidated net profit of Rs 197.24 crore in the year-ago period, the company said in a regulatory filing.

Consolidated revenue from operations in the quarter rose to Rs 2,469.7 crore from Rs 2,116.25 crore a year earlier.

International business sales stood at Rs 1,493 crore, up 25.7 per cent year-on-year, supported by growth across markets, base business ramp-up and new launches.

Domestic business sales were at Rs 977 crore, up 5.2 percent year-on-year. The company said the softer performance was largely due to its Zuventus Healthcare Ltd portfolio and team reorganisation.

Total expenses in the fourth quarter increased to Rs 2,142.82 crore from Rs 1,849.7 crore in the corresponding period last fiscal.

For FY26, consolidated net profit rose to Rs 941.27 crore from Rs 707.47 crore in FY25.

Consolidated revenue from operations in FY26 stood at Rs 9,203.54 crore as against Rs 7,896 crore in the previous financial year.

Commenting on the performance, Managing Director and CEO Satish Mehta said the company delivered strong financial performance in FY26, the first year of its five-year strategic plan, with over USD 1 billion in revenue and 16.6 per cent growth. International markets showed robust momentum while domestic business recorded steady growth, he added.

He said the company’s R&D pipeline in complex injectables and biosimilars remains a key driver of future value, with focus on sustainable growth and margin expansion.

The company said its board has approved the re-appointment of Mehta as Managing Director for a further period of five years from April 1, 2027, subject to shareholders’ approval.

The board has also recommended a final dividend of Rs 3.6 per fully paid-up equity share of Rs 10 each for the financial year ended March 2026, subject to shareholders’ approval.